Financial Data and Key Metrics Changes - Adjusted diluted EPS increased by 9% to $4.08, driven by strong performance in the U.S. Healthcare Solutions segment [14] - Consolidated revenue reached $85.9 billion, up 5.5%, attributed to growth in both reportable segments [14] - Consolidated gross profit rose by 18% to $3.0 billion, with a gross profit margin of 3.48%, an increase of 37 basis points [15] - Operating income increased by 12% to $1.1 billion, reflecting strong execution and growth in the U.S. Healthcare Solutions segment [15] Business Line Data and Key Metrics Changes - U.S. Healthcare Solutions revenue was $76.2 billion, up 5%, with operating income increasing by 21% to $831 million, driven by the RCA acquisition and specialty growth [18] - International Healthcare Solutions revenue was $7.6 billion, up approximately 10% on an as-reported basis, but operating income decreased by 14% due to timing of manufacturer price adjustments [20][21] - Revenue in Other was $2.1 billion, up 6%, primarily due to growth at MWI Animal Health [21] Market Data and Key Metrics Changes - Strong sales growth in the U.S. for GLP-1 products increased by $1 billion or 11% over the prior year quarter [14] - International Healthcare Solutions segment experienced a decline in operating income, largely due to lower performance in the European distribution business [21] Company Strategy and Development Direction - Cencora's strategy focuses on strengthening leadership in specialty pharmaceuticals, leading with market leaders, and enhancing patient access to pharmaceuticals [7] - The acquisition of OneOncology is expected to drive significant value creation and support long-term growth [13] - The company aims to leverage its MSO platform to enhance solutions for providers and biopharma, focusing on clinical research and data-driven insights [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's long-term guidance, citing strong performance despite headwinds from lost customers [33] - The company anticipates continued growth in the U.S. Healthcare Solutions segment, with adjusted operating income growth now expected to be in the range of 14%-16% [24] - Management highlighted the importance of strategic partnerships with health systems to drive future growth [42] Other Important Information - The company has paused share repurchases to prioritize debt paydown following the OneOncology acquisition [16][75] - Adjusted free cash flow for the quarter was negative $2.4 billion, with expectations of approximately $3 billion for the full year [17] Q&A Session Summary Question: Operating income growth and deceleration concerns - Management clarified that adjusted operating income growth in the U.S. was 21% in the December quarter, and they remain confident in long-term guidance despite challenging comparisons [31][34] Question: MSO platform opportunities for AOI growth - Management discussed leveraging clinical trial excellence and revenue cycle management capabilities across the MSO platform to drive growth [38][40] Question: Strategic partnerships with health systems - Management emphasized the importance of understanding health systems' strategies to foster growth in specialty pharmaceuticals [42] Question: International segment timing dynamics - Management explained that the international segment faced a timing difference for manufacturer price adjustments, but they expect a rebound in performance [54] Question: Revenue guidance changes and OneOncology contribution - Management indicated that OneOncology's impact on revenue guidance is limited due to its lower revenue business model but will enhance operating income margins [80]